TCRX Stock Analysis: Buy, Sell, or Hold?
TCRX - TScan Therapeutics, Inc. Common Stock
$0.90
-0.02 (-2.42%)
▼
5d:
+5.97%
30d:
-15.22%
90d:
-12.75%
HOLD
MODERATE Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Aug 11, 2026
Get Alerted When TCRX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: TCRX shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: TCRX shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: TCRX is currently trading at $0.90, which is considered oversold relative to its 30-day fair value range of $0.92 to $1.05.
Technical Outlook: Technically, TCRX is showing sideways momentum. The price is currently testing key support at $0.94. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: TCRX has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $6.00 (+551.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, TCRX is showing sideways momentum. The price is currently testing key support at $0.94. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: TCRX has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $6.00 (+551.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.92 -
$1.05
Company Quality Score
50/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 551.5% below Wall St target ($6.00)
Trading Range Analysis
30-Day Trading Range
$0.92 -
$1.05
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.94
Resistance Level
$1.13
Current Trend
Sideways
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.04
Wall Street Target
$6.00
(+551.5%)
Revenue Growth (YoY)
-54.8%
Share & Embed Analysis
Last updated: June 24, 2026 10:48 AM ET
Data refreshes hourly during market hours. Next update: 11:48 AM
Data refreshes hourly during market hours. Next update: 11:48 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TCRX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$27 | 56 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$412 | 57 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$197 | 61 BUY |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 54 HOLD |
|
GPCR
Structure Therapeutics I… |
STRONG BUY
14 analysts |
$105 | 57 HOLD |
